Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Drug Discovery Today

• Publication date

  2014-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.drudis.2014.03.028PMID 24721226
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Emerging cell and cytokine targets in rheumatoid arthritis

  2014cited by this paper
• Selective Inhibition of BTK Prevents Murine Lupus and Antibody-Mediated Glomerulonephritis

  2013cited by this paper
• Ibrutinib and novel BTK inhibitors in clinical development

  2013cited by this paper
• Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans

  2013cited by this paper
• Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice.

  2012cited by this paper
• Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus

  2012cited by this paper
• RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents

  2012cited by this paper
• The pathogenesis of rheumatoid arthritis.

  2011cited by this paper
• Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.

  2011cited by this paper
• Antiarthritis Effect of a Novel Bruton's Tyrosine Kinase (BTK) Inhibitor in Rat Collagen-Induced Arthritis and Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling: Relationships between Inhibition of BTK Phosphorylation and Efficacy

  2011cited by this paper
• The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells

  2011cited by this paper
• Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis.

  2011cited by this paper
• Significant Species Difference in Amide Hydrolysis of GDC-0834, a Novel Potent and Selective Bruton's Tyrosine Kinase Inhibitor

  2011cited by this paper
• The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

  2010cited by this paper
• Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain

  2009cited by this paper
• Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future.

  2008cited by this paper
• Dual Functions of Bruton’s Tyrosine Kinase and Tec Kinase during Fcγ Receptor-Induced Signaling and Phagocytosis1

  2008cited by this paper
• The pathogenesis of rheumatoid arthritis.

  2007cited by this paper
• Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase

  2007cited by this paper
• The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.

  2006cited by this paper
• Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.

  2006cited by this paper
• Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

  2004cited by this paper
• Essential Role of Fcγ Receptors in Anti-Type II Collagen Antibody-Induced Arthritis

  2003cited by this paper
• Essential role of Fc gamma receptors in anti-type II collagen antibody-induced arthritis.

  2003influential reference
• Roles of Fc receptors in autoimmunity

  2002cited by this paper
• Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes.

  2001cited by this paper
• B cell development pathways.

  2001cited by this paper
• Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase

  2001cited by this paper
• A B-cell receptor-specific selection step governs immature to mature B cell differentiation.

  2000influential reference
• Induction and Suppression of Collagen-Induced Arthritis Is Dependent on Distinct Fcγ Receptors

  2000cited by this paper
• Deletion of Fcγ Receptor IIB Renders H-2b Mice Susceptible to Collagen-induced Arthritis

  1999cited by this paper
• Importance of CD23 for collagen-induced arthritis: delayed onset and reduced severity in CD23-deficient mice.

  1999cited by this paper
• B cell‐deficient mice do not develop type II collagen‐induced arthritis (CIA)

  1998influential reference
• Btk function in B cell development and response.

  1998influential reference
• Involvement of Bruton's Tyrosine Kinase in FcεRI-dependent Mast Cell Degranulation and Cytokine Production

  1998cited by this paper
• In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death.

  1997cited by this paper
• Defective B cell development and function in Btk-deficient mice.

  1995cited by this paper
• Impaired expansion of mouse B cell progenitors lacking Btk.

  1995cited by this paper
• Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice.

  1993cited by this paper
• Genes on the X chromosome affect development of collagen‐induced arthritis in mice

  1993influential reference
• Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia.

  1993cited by this paper

• Journey of B Cell Dysregulation in Rheumatoid Arthritis: Insights from Immunogenomics

  2025cites this paper
• Inhibition of Bruton's tyrosine kinase restricts neuroinflammation following intracerebral hemorrhage

  2025cites this paper
• Effects of orelabrutinib, a BTK inhibitor, on antibody‐mediated platelet destruction in primary immune thrombocytopenia

  2025cites this paper
• Beyond relapses: How BTK inhibitors are shaping the future of progressive MS treatment

  2025cites this paper
• Discovery of Imidazo[1,2-b]pyridazine Derivatives as Potent and Highly Selective Irreversible Bruton's Tyrosine Kinase (BTK) Inhibitors.

  2025cites this paper
• Next generation Bruton's tyrosine kinase inhibitors - characterization of in vitro potency and selectivity.

  2025cites this paper
• Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study.

  2025cites this paper
• Leflunomide Applicability in Rheumatoid Arthritis: Drug Delivery Challenges and Emerging Formulation Strategies

  2025cites this paper
• Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors.

  2024cites this paper
• Critical role of G protein-coupled receptor 40 in B cell response and the pathogenesis of rheumatoid arthritis in mice and patients.

  2024cites this paper
• Dysregulation of Toll-Like Receptor Signaling-Associated Gene Expression in X-Linked Agammaglobulinemia: Implications for Correlations Genotype-Phenotype and Disease Expression

  2024cites this paper
• A phase II study of Bruton’s tyrosine kinase inhibition for the prevention of anaphylaxis

  2023cites this paper
• Bruton’s Tyrosine Kinase in Ankylosing Spondylitis

  2023cites this paper
• A pilot study of orelabrutinib treatment in three cases of refractory/relapsed autoimmune haemolytic anaemia/Evans syndrome

  2023cites this paper
• Safety, pharmacokinetics and pharmacodynamics of HWH486 capsules in healthy adults: A randomized, double-blind, placebo-controlled, phase I dose-escalation study.

  2023cites this paper
• Bruton’s tyrosine kinase as a promising therapeutic target for multiple sclerosis

  2023cites this paper
• Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?

  2022cites this paper
• Recent development of BTK-based dual inhibitors in the treatment of cancers.

  2022cites this paper
• Synergistic effect of Bruton's tyrosine kinase and TNF-α in the regulation of rheumatoid arthritis and underlying mechanisms.

  2022cites this paper
• Comparison of Intermolecular Interactions of Irreversible and Reversible Inhibitors with Bruton’s Tyrosine Kinase via Molecular Dynamics Simulations

  2022cites this paper
• Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases

  2021cites this paper
• Inhibition of Bruton Tyrosine Kinase Reduces Neuroimmune Cascade and Promotes Recovery after Spinal Cord Injury

  2021cites this paper
• Exploration of benzofuran-based compounds as potent and selective Plasmodium falciparum glycogen synthase kinase-3 (PfGSK-3) inhibitors.

  2021cites this paper
• Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases

  2021cites this paper
• Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease

  2021cites this paper
• Three efficient chemometrics assisted fluorimetric detection methods for interference-free, rapid, and simultaneous determination of ibrutinib and pralatrexate in various complicated biological fluids.

  2021cites this paper
• Novel injectable carrier based corticosteroid therapy for treatment of rheumatoid arthritis and osteoarthritis

  2021cites this paper
• US FDA‐Approved Small‐Molecule Kinase Inhibitors for Cancer Therapy

  2021cites this paper
• Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors.

  2021cites this paper
• Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.

  2021cites this paper
• Leukotriene B4 licenses inflammasome activation to enhance skin host defense

  2020cites this paper
• Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS‐986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo‐controlled trial in healthy participants

  2020cites this paper
• Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double‐Blind, Phase II Trial

  2020cites this paper
• Computational Approaches for the Design of (Mutant-)Selective Tyrosine Kinase Inhibitors: State-of-the-Art and Future Prospects.

  2020cites this paper
• Etanercept Inhibits B Cell Differentiation by Regulating TNFRII/TRAF2/NF-κB Signaling Pathway in Rheumatoid Arthritis

  2020cites this paper
• Development of piperidinyl dipyrrrolopyridine-based dual inhibitors of Janus kinase and Bruton’s tyrosine kinase: a potential therapeutic probability to deal with rheumatoid arthritis

  2020cites this paper
• Promising targets and drugs in rheumatoid arthritis

  2020cites this paper
• Bruton's tyrosine kinase inhibition attenuates oxidative stress in systemic immune cells and renal compartment during sepsis-induced acute kidney injury in mice.

  2020cites this paper
• Molecular therapeutic strategies in neurodegenerative diseases and injury

  2020cites this paper
• The prospects for targeting FcR as a novel therapeutic strategy in rheumatoid arthritis.

  2020cites this paper
• Immunosuppressive agents for rheumatoid arthritis: a systematic review of clinical trials and their current development stage

  2020cites this paper
• A highly sensitive LC-MS/MS method to determine novel Bruton's tyrosine kinase inhibitor spebrutinib: application to metabolic stability evaluation

  2019cites this paper
• Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton's Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis.

  2019cites this paper
• Nanoparticle-delivered siRNA targeting Bruton's tyrosine kinase for rheumatoid arthritis therapy.

  2019cites this paper
• Inhibition of Bruton's tyrosine kinase and IL-2 inducible T-cell kinase suppresses both neutrophilic and eosinophilic airway inflammation in a cockroach allergen extract-induced mixed granulocytic mouse model of asthma using preventative and therapeutic strategy.

  2019cites this paper
• The Use of Conformational Restriction in Medicinal Chemistry.

  2019cites this paper
• Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis: phase I to Ⅱ clinical trials

  2019cites this paper
• Bayesian machine learning to discover Bruton’s tyrosine kinase inhibitors

  2019cites this paper
• Brutons Tyrosine Kinase (Btk) Inhibitor Tirabrutinib Suppresses Osteoclastogenesis and Inflammation in a Mouse CollagenInduced Arthritis Model

  2019cites this paper
• Bruton’s Tyrosine Kinase Inhibition Promotes Myelin Repair

  2019cites this paper
• Sterile particle-induced inflammation is mediated by macrophages releasing IL-33 through a Bruton’s tyrosine kinase-dependent pathway

  2019cites this paper
• Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.

  2019cites this paper
• Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models

  2019cites this paper
• Pharmacophore modeling and virtual screening in search of novel Bruton’s tyrosine kinase inhibitors

  2019cites this paper
• Determination of Real Time in Vivo Drug Receptor Occupancy for a Covalent Binding Drug as a Clinical Pharmacodynamic Biomarker by Immunocapture-LC-MS/MS.

  2019cites this paper
• A novel Bruton's tyrosine kinase inhibitor, acalabrutinib, suppresses osteoclast differentiation and Porphyromonas gingivalis lipopolysaccharide-induced alveolar bone resorption.

  2018cites this paper
• The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.

  2018cites this paper
• Molecular Modeling Studies on Carbazole Carboxamide Based BTK Inhibitors Using Docking and Structure-Based 3D-QSAR

  2018cites this paper
• Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis.

  2018cites this paper
• Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies

  2018cites this paper
• Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor

  2017cites this paper
• Discovery of 3-morpholino-imidazole[1,5-a]pyrazine BTK inhibitors for rheumatoid arthritis.

  2017cites this paper
• Anti-tumor efficacy study of the Bruton’s tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 in combination with rituximab

  2017influential citation
• Evolution of Small-Molecule Immunology Research—Changes Since CMC II

  2017cites this paper
• Characterization of PKACα enzyme kinetics and inhibition in an HPLC assay with a chromophoric substrate.

  2017cites this paper
• Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants

  2017cites this paper
• Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile

  2017cites this paper
• Discovery of novel BTK inhibitors with carboxylic acids.

  2017cites this paper
• Structure-activity relationship investigation for benzonaphthyridinone derivatives as novel potent Bruton's tyrosine kinase (BTK) irreversible inhibitors.

  2017cites this paper
• A quantitative mechanistic PK/PD model directly connects Btk target engagement and in vivo efficacy

  2017cites this paper
• Discovery of 8-Amino-imidazo[1,5-a]pyrazines as Reversible BTK Inhibitors for the Treatment of Rheumatoid Arthritis.

  2016cites this paper
• Recent advances in primary Sjogren's syndrome

  2016cites this paper
• Open Peer Review

  2016cites this paper
• Btk inhibition treats TLR7/IFN driven murine lupus.

  2016cites this paper
• Investigational Bruton’s tyrosine kinase inhibitors for the treatment of rheumatoid arthritis

  2016cites this paper
• Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked

  2016cites this paper
• Recent developments in the chromatographic bioanalysis of approved kinase inhibitor drugs in oncology.

  2016cites this paper
• Preclinical Evaluation of Synergistic Drug Combinations in Acute Myeloid Leukemia

  2016cites this paper
• Liquid chromatography-tandem mass spectrometric assay for the simultaneous determination of the irreversible BTK inhibitor ibrutinib and its dihydrodiol-metabolite in plasma and its application in mouse pharmacokinetic studies.

  2016cites this paper
• Small Molecule Reversible Inhibitors of Bruton's Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177).

  2016cites this paper
• Identification of Covalent Binding Sites Targeting Cysteines Based on Computational Approaches.

  2016cites this paper
• Small-molecule kinase inhibitors: an analysis of FDA-approved drugs.

  2016cites this paper
• Quantitative structure–activity relationship study on BTK inhibitors by modified multivariate adaptive regression spline and CoMSIA methods

  2015cites this paper
• T Cell Migration in Rheumatoid Arthritis

  2015cites this paper
• DNMT1 activates the canonical Wnt signaling in rheumatoid arthritis model rats via a crucial functional crosstalk between miR-152 and the DNMT1, MeCP2.

  2015cites this paper
• Bruton’s Tyrosine Kinase (BTK) Beyond B Lymphocytes: A Protein Kinase with Relevance in Innate Immunity

  2015cites this paper
• Bruton’s tyrosine kinase in chronic inflammation: from pathophysiology to therapy

  2015influential citation
• Pyrrolo[2,3-b]pyridine derivatives as potent Bruton's tyrosine kinase inhibitors.

  2015cites this paper
• [Effector B cells in autoimmune diseases].

  2015cites this paper
• The evolution of our understanding of macrophages and translation of findings toward the clinic

  2015cites this paper
• Evaluation of ligation methods and the synthesis of a specific PNA-encoded peptide library

  2015cites this paper
• Small-molecule inhibitors for autoimmune arthritis: success, failure and the future.

  2015cites this paper
• Advances in kinase targeting: current clinical use and clinical trials.

  2014cites this paper
• Molecular targeted therapy against B cells in multiple sclerosis

  2014cites this paper
• Inducible tyrosine kinase inhibitors: a review of the patent literature (2010 – 2013)

  2014cites this paper
• Small-molecule therapeutics in rheumatoid arthritis: scientific rationale, efficacy and safety.

  2014cites this paper